文献速递其他结缔组织病血管炎

系统性硬化症患者肺动脉高压早期筛查的长期结局:系统综述与荟萃分析

Screening for the early detection of pulmonary arterial hypertension in patients with systemic sclerosis: A systematic review and meta-analysis of long-term outcomes.
PubMed 文献 · Semin Arthritis Rheum · 2021-04-04

该系统综述与荟萃分析检索至2019年3月的研究,纳入15篇文献综述筛查方案、6篇进行荟萃分析,发现筛查诊断的系统性硬化症相关肺动脉高压(SSc-PAH)患者生存改善,诊断时风险分层参数更优,但证据来自注册数据、横断面和队列研究,无随机对照试验。

要点

  • 筛查诊断的SSc-PAH患者生存改善,诊断时风险分层参数更优。
  • 现有PAH筛查方案多样,缺乏统一标准。
  • 证据来自观察性研究,无随机对照试验支持。

核心结论

  • 对病程不一的SSc患者进行系统筛查以早期发现PAH具有长期获益,筛查队列生存改善且诊断时更可能具备较好预后因素。

研究设计与样本

  • 系统综述与荟萃分析,检索Medline、Embase、Cochrane Central Register of Controlled Trials和Database of Systematic Reviews至2019年3月12日。
  • 纳入接受任何方案筛查PAH的SSc患者的研究(摘要或全文),最终15篇用于筛查方法系统综述,6篇用于荟萃分析。
  • 使用QUADAS-2工具评估偏倚风险。

主要发现

  • 系统综述显示PAH筛查方案存在多种不同协议。
  • 筛查人群在PAH诊断时报告有更好的风险分层参数。
  • 荟萃分析显示筛查诊断的SSc-PAH患者生存改善。
  • 筛查者在PAH诊断时趋向于有更好的风险分层参数,但并非所有差异均具统计学显著性。

临床怎么用

  • 国际建议对无症状SSc患者每年筛查以早期发现PAH,本综述支持该系统筛查策略可带来长期生存获益。

局限性

  • 无SSc患者PAH筛查的随机对照试验,本综述证据来自注册数据、横断面和队列研究的发表文献。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Systemic sclerosis (scleroderma, SSc) is a chronic multisystem autoimmune disease characterised by fibrosis of the skin and internal organs and vasculopathy. One of the major contributors to mortality in patients with SSc is pulmonary arterial hypertension (PAH). International recommendations advise annual screening for the early detection of PAH in asymptomatic patients with SSc. OBJECTIVES: To evaluate by systematic review current measures employed for screening for PAH. To summarise by meta-analysis the current evidence for long-term outcomes of screening for PAH in SSc. METHODS: Manuscripts published until 12th March 2019 were identified through searching Medline, Embase and Cochrane Central Register of Controlled Trials and Database of Systematic Reviews. Eligible studies included abstracts or full reports investigating patients with SSc undergoing screening by any protocol to detect PAH. Risk of bias was assessed with reference to the QUADAS-2 tool. RESULTS: The review resulted in 580 unique citations with 15 manuscripts included for final systematic review of screening methods, and six for meta-analysis. The systematic review demonstrated that there are varying protocols for screening for PAH. Screened populations were reported to have better risk stratification parameters at PAH diagnosis. Meta-analysis showed improved survival in patients with SSc-PAH diagnosed as a result of screening. There were trends towards having better risk stratification parameters at PAH diagnosis in those screened, although not all of these were statistically significant. LIMITATIONS: There are no randomised controlled trials of screening for PAH in patients with SSc and the evidence presented in this review is derived from publications of registry data, cross-sectional and cohort studies. CONCLUSIONS: This review demonstrates long-term benefit through the systematic screening of patients with SSc of varying disease duration for the early detection of PAH. Screened cohorts had improved survival, and were more likely to have better prognostic factors at the time of diagnosis with PAH.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Brown Z, Proudman S, Morrisroe K, et al. Screening for the early detection of pulmonary arterial hypertension in patients with systemic sclerosis: A systematic review and meta-analysis of long-term outcomes. Semin Arthritis Rheum. 2021. PMID: 33857705. doi:10.1016/j.semarthrit.2021.03.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。